network member

University of Iowa Holden Comprehensive Cancer Center

200 Hawkins Dr., 7970 JPP Iowa City, IA 52242
University of Iowa Holden Comprehensive Cancer Center

About Network Member

Founded in 1980, the Holden Comprehensive Cancer Center at the University of Iowa has been an NCI comprehensive cancer center since 2001. The Center is dedicated to bringing the finest cancer care and research to Iowa and beyond. Research at Holden is organized into four research programs: cancer genes and pathways, experimental therapeutics, free radical metabolism and imaging, and cancer epidemiology and population science. The Center promotes interactive cancer research, provides health care related to the prevention, detection, and treatment of cancer, and educates cancer professionals and the citizens of Iowa about cancer. Holden is also organized around specific cancer types through its Multidisciplinary Oncology Groups which include a dozen multidisciplinary teams that are involved in both clinical care and research. The Center enrolls many patients in its active program of early phase clinical trials and also supports clinical and translational research done in collaboration with other cancer centers through efforts including the Iowa/Mayo Lymphoma SPORE, the National Clinical Trials Network and the Big Ten Cancer Research Consortium. Holden also is the only cancer center in the nation with a SPORE grant to study Neuroendocrine tumors. Additional research is taking place through the efforts of multidisciplinary teams involved in cancer prevention, cancer and obesity, stem cell transplantation and molecular oncology. Holden has an active molecular oncology program that includes a Molecular Tumor Board and a Molecular Pathology team that is CLIA certified and CAP accredited and conducts multigene cancer hotspot mutation testing with next generation sequencing. The Center supports 11 shared research resources that provide support to cancer investigators exploring molecular and cellular aspects of cancer, clinical trials and population studies. Holden has established prospective registries linked to biospecimens for select cancer types know as the Molecular Epidemiology Resources. Over 4000 subjects have been enrolled in these registries. Website: Holden Comprehensive Cancer Center at the University of Iowa
Currently Enrolling

HCRN-BRE20-468

A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
Cancer areas:Breast
Fred & Pamela Buffett Cancer Center
New York University Cancer Institute
Orlando Health Cancer Institute
Parkview Research Center
Penn State Cancer Institute
Providence Cancer Institute
Rutgers Cancer Institute of New Jersey
The Ohio State University
Tufts Medical Center
University of Alabama at Birmingham Comprehensive Cancer Center
University of Arizona Cancer Center
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Michigan Health-West
University of Michigan Rogel Cancer Center
University of Virginia Cancer Center
University of Wisconsin Carbone Cancer Center
Currently Enrolling

HCRN-GU16-243

PhAse I/II StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER – (ADAPT-BLADDER) HCRN GU16-243
Columbia University Irving Medical Center
Fox Chase Cancer Center
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
University of Iowa Holden Comprehensive Cancer Center
Currently Enrolling

HCRN-LUN21-530

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART)
Cancer areas:Lung
Barbara Ann Karmanos Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Virginia Cancer Center
Currently Enrolling

HCRN-MCC20-443

A Single Arm Phase II Study with Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination with Immunotherapy for Patients with Merkel Cell Cancer (iPRRT Study)
University of Iowa Holden Comprehensive Cancer Center
Weill Cornell Medicine
Currently Enrolling

BTCRC-HEM15-027

Phase I/II Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma: BTCRC-HEM15-027
Cancer areas:Lymphoma
Masonic Cancer Center, University of Minnesota
University of Iowa Holden Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

BTCRC-HN17-111

Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111
Cancer areas:Head and Neck
Masonic Cancer Center, University of Minnesota
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
University of Michigan Rogel Cancer Center
University of Wisconsin Carbone Cancer Center
Currently Enrolling

BTCRC-LUN18-153

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Cancer areas:Lung
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Moffitt Cancer Center
Penn State Cancer Institute
Providence Cancer Institute
Rutgers Cancer Institute of New Jersey
The Ohio State University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Virginia Cancer Center
Virginia Commonwealth University
Currently Enrolling

BTCRC-LUN20-462

A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab as Second Line Treatment for Small Cell Lung Cancer
Cancer areas:Lung
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
The Ohio State University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

HCRN-MEL16-252

Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252
Cancer areas:Melanoma
Fox Chase Cancer Center
Masonic Cancer Center, University of Minnesota
Mayo Clinic
Nebraska Cancer Specialists
Providence Cancer Institute
University of Iowa Holden Comprehensive Cancer Center
Enrollment Closed

BTCRC-BRE18-337

Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers: Big Ten Cancer Research Consortium BTCRC-BRE18-337
Cancer areas:Breast
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

BTCRC-LUN18-363

A Phase II Study of Chemo-Immunotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Big Ten Cancer Research Consortium BTCRC-LUN18-363
Cancer areas:Lung
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
The Ohio State University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center